News
CMOPF
97.17
NaN%
--
Weekly Report: what happened at CMOPF last week (0511-0515)?
Weekly Report · 5d ago
Cosmo completes Phase II recruitment for novel ulcerative colitis therapy
TipRanks · 5d ago
Cosmo Announces Completion of Phase II Enrolment in Distal Ulcerative Colitis Program
Newsfile · 5d ago
COSMO Pharmaceuticals N.V. (0RGI) Gets a Buy from Kepler Capital
TipRanks · 05/13 01:39
Weekly Report: what happened at CMOPF last week (0504-0508)?
Weekly Report · 05/11 10:45
COSMO Pharmaceuticals N.V. (0RGI) Receives a Buy from Kepler Capital
TipRanks · 05/09 01:40
Weekly Report: what happened at CMOPF last week (0427-0501)?
Weekly Report · 05/04 10:41
Kepler Capital Sticks to Its Buy Rating for COSMO Pharmaceuticals N.V. (0RGI)
TipRanks · 04/30 01:49
Weekly Report: what happened at CMOPF last week (0420-0424)?
Weekly Report · 04/27 10:45
Weekly Report: what happened at CMOPF last week (0413-0417)?
Weekly Report · 04/20 10:40
Cosmo price target raised to CHF 160 from CHF 130 at H.C. Wainwright
TipRanks · 04/20 10:20
Kepler Capital Keeps Their Buy Rating on COSMO Pharmaceuticals N.V. (0RGI)
TipRanks · 04/17 01:36
Cosmo’s Clascoterone Delivers Strong 12‑Month Data in Male Hair Loss, Paving Way for 2027 Filings
TipRanks · 04/15 05:34
Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which are Statistically Significant
Newsfile · 04/15 05:07
Weekly Report: what happened at CMOPF last week (0406-0410)?
Weekly Report · 04/13 10:45
Cosmo Shareholders Approve All AGM Resolutions and EUR 2.10 Dividend
TipRanks · 04/10 13:40
Cosmo Pharmaceuticals N.V. declares EUR 2.10 dividend
Seeking Alpha · 04/10 13:26
Voting Results of Cosmo's 2026 AGM
Newsfile · 04/10 13:16
Weekly Report: what happened at CMOPF last week (0330-0403)?
Weekly Report · 04/06 10:45
Weekly Report: what happened at CMOPF last week (0323-0327)?
Weekly Report · 03/30 10:46
More
Webull provides a variety of real-time CMOPF stock news. You can receive the latest news about Cosmo Pharmaceuticals Nv through multiple platforms. This information may help you make smarter investment decisions.
About CMOPF
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases, dermatology, and healthtech. Its development pipeline includes Distal Ulcerative Colitis, Bile Acid Diarrhea, Solid Tumors, and AI Augmented Endoscopy. The Company's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, which is used for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo, which is used for the treatment of travelers’ diarrhea (TD); Methylene Blue MMX, which is a diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy, and Winlevi, which is used for the treatment of acne. It also develops medical devices to assist with clinical decision-making.